Invizyne Technologies (IZTC) Competitors $16.90 -0.55 (-3.15%) As of 02/28/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsInsider TradesOwnershipSEC FilingsTrends IZTC vs. MREO, UPB, SNDL, PROK, KROS, CMRX, CMPX, PRTC, CDXC, and KMDAShould you be buying Invizyne Technologies stock or one of its competitors? The main competitors of Invizyne Technologies include Mereo BioPharma Group (MREO), Upstream Bio (UPB), SNDL (SNDL), ProKidney (PROK), Keros Therapeutics (KROS), Chimerix (CMRX), Compass Therapeutics (CMPX), PureTech Health (PRTC), ChromaDex (CDXC), and Kamada (KMDA). These companies are all part of the "pharmaceutical products" industry. Invizyne Technologies vs. Mereo BioPharma Group Upstream Bio SNDL ProKidney Keros Therapeutics Chimerix Compass Therapeutics PureTech Health ChromaDex Kamada Invizyne Technologies (NASDAQ:IZTC) and Mereo BioPharma Group (NASDAQ:MREO) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, profitability, media sentiment, community ranking, risk, institutional ownership, earnings, dividends and analyst recommendations. Which has higher valuation & earnings, IZTC or MREO? Invizyne Technologies has higher earnings, but lower revenue than Mereo BioPharma Group. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioInvizyne TechnologiesN/AN/AN/AN/AN/AMereo BioPharma Group$1M359.94-$29.47MN/AN/A Does the MarketBeat Community favor IZTC or MREO? Mereo BioPharma Group received 49 more outperform votes than Invizyne Technologies when rated by MarketBeat users. CompanyUnderperformOutperformInvizyne TechnologiesN/AN/AMereo BioPharma GroupOutperform Votes4979.03% Underperform Votes1320.97% Is IZTC or MREO more profitable? Company Net Margins Return on Equity Return on Assets Invizyne TechnologiesN/A N/A N/A Mereo BioPharma Group N/A N/A N/A Does the media prefer IZTC or MREO? In the previous week, Invizyne Technologies and Invizyne Technologies both had 1 articles in the media. Mereo BioPharma Group's average media sentiment score of 1.71 beat Invizyne Technologies' score of -1.00 indicating that Mereo BioPharma Group is being referred to more favorably in the news media. Company Overall Sentiment Invizyne Technologies Negative Mereo BioPharma Group Very Positive Do analysts recommend IZTC or MREO? Mereo BioPharma Group has a consensus target price of $7.83, indicating a potential upside of 237.64%. Given Mereo BioPharma Group's stronger consensus rating and higher possible upside, analysts clearly believe Mereo BioPharma Group is more favorable than Invizyne Technologies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Invizyne Technologies 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Mereo BioPharma Group 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 3 Strong Buy rating(s) 3.43 Do insiders and institutionals hold more shares of IZTC or MREO? 62.8% of Mereo BioPharma Group shares are owned by institutional investors. 4.1% of Mereo BioPharma Group shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. SummaryMereo BioPharma Group beats Invizyne Technologies on 9 of the 9 factors compared between the two stocks. Get Invizyne Technologies News Delivered to You Automatically Sign up to receive the latest news and ratings for IZTC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IZTC vs. The Competition Export to ExcelMetricInvizyne TechnologiesBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$105.66M$3.08B$5.81B$8.39BDividend YieldN/A1.51%4.75%3.98%P/E RatioN/A28.6624.9519.25Price / SalesN/A403.91375.54110.22Price / CashN/A168.6838.0534.58Price / BookN/A3.487.334.28Net IncomeN/A-$71.55M$3.18B$247.04M7 Day Performance-4.57%-6.66%-4.42%-4.36%1 Month Performance-10.25%-9.02%-6.07%-5.60%1 Year PerformanceN/A-22.49%11.42%3.38% Invizyne Technologies Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IZTCInvizyne TechnologiesN/A$16.90-3.2%N/AN/A$105.66MN/A0.00N/ANegative NewsGap UpMREOMereo BioPharma Group2.4316 of 5 stars$2.69-5.6%$7.83+191.2%-41.6%$442.17M$1M0.0040Positive NewsUPBUpstream BioN/A$8.22+3.0%$56.50+587.3%N/A$440.57M$2.21M0.0038Upcoming EarningsSNDLSNDL3.7916 of 5 stars$1.67-5.6%$3.25+94.6%+13.0%$438.84M$673.33M-5.392,516PROKProKidney1.9597 of 5 stars$1.50flat$4.50+200.0%-32.0%$437.49MN/A-2.733KROSKeros Therapeutics3.3478 of 5 stars$10.79-2.1%$52.56+387.1%-83.9%$437.10M$150,000.00-2.07100Earnings ReportAnalyst RevisionNews CoverageCMRXChimerix4.3232 of 5 stars$4.76-7.6%$9.00+89.1%+330.8%$428.10M$159,000.00-5.0690Upcoming EarningsCMPXCompass Therapeutics3.6382 of 5 stars$3.11+6.5%$11.38+265.8%+43.7%$427.91MN/A-8.4120Earnings ReportShort Interest ↑Analyst RevisionGap UpPRTCPureTech Health1.8592 of 5 stars$17.82-3.5%$45.00+152.5%-31.7%$426.65M$3.33M0.00100Gap UpCDXCChromaDex4.252 of 5 stars$5.50+1.5%$8.00+45.5%+241.6%$420.11M$91.67M550.55120KMDAKamada4.0404 of 5 stars$7.23-3.1%$14.50+100.6%+6.6%$415.58M$158.38M25.82360 Related Companies and Tools Related Companies Mereo BioPharma Group Alternatives Upstream Bio Alternatives SNDL Alternatives ProKidney Alternatives Keros Therapeutics Alternatives Chimerix Alternatives Compass Therapeutics Alternatives PureTech Health Alternatives ChromaDex Alternatives Kamada Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:IZTC) was last updated on 3/4/2025 by MarketBeat.com Staff From Our PartnersHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredLeaked Trump video exposes his secret stocksTen investments secretly owned by Trump’s biggest backers. Ten investments intrinsically tied to the polici...Porter & Company | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredElon Social Security shock?“A Maniacal Sense of Urgency” We could be just days away from Elon Musk launching his next big venture. One...Altimetry | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Invizyne Technologies Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Invizyne Technologies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free IZTC Stock Alerts